Frontiers in Immunology

Front Immunol. 9: 161

A Prominent Role of Interleukin-18 in Acetaminophen-Induced Liver Injury Advocates Its Blockage for Therapy of Hepatic Necroinflammation

Malte Bachmann¹, Josef Pfeilschifter¹, Heiko Mühl¹*

¹Pharmazentrum Frankfurt/ZAFES, University Hospital Goethe-University Frankfurt am Main, Frankfurt am Main, Germany

Edited by: Detlef Neumann, Hannover Medical School, Germany

Reviewed by: Ryosuke Uchiyama, Hyogo College of Medicine, Japan; Paul Proost, KU Leuven, Belgium

*Correspondence: Heiko Mühl, h.muehl@em.uni-frankfurt.de

Specialty section: This article was submitted to Cytokines and Soluble Mediators in Immunity, a section of the journal Frontiers in Immunology

Copyright © 2018 Bachmann, Pfeilschifter and Mühl.

DOI: 10.3389/fimmu.2018.00161

Published online: 08 February 2018

Abstract

Acetaminophen [paracetamol, N-acetyl-p-aminophenol (APAP)]-induced acute liver injury (ALI) not only remains a persistent clinical challenge but likewise stands out as well-characterized paradigmatic model of drug-induced liver damage. APAP intoxication associates with robust hepatic necroinflammation the role of which remains elusive with pathogenic but also pro-regenerative/-resolving functions being ascribed to leukocyte activation. Here, we shine a light on and put forward a unique role of the interleukin (IL)-1 family member IL-18 in experimental APAP-induced ALI. Indeed, amelioration of disease as previously observed in IL-18-deficient mice was further substantiated herein by application of the IL-18 opponent IL-18-binding protein (IL-18BPd:Fc) to wild-type mice. Data altogether emphasize crucial pathological action of this cytokine in APAP toxicity. Adding recombinant IL-22 to IL-18BPd:Fc further enhanced protection from liver injury. In contrast to IL-18, the role of prototypic pro-inflammatory IL-1 and tumor necrosis factor-α is controversially discussed with lack of effects or even protective action being repeatedly reported. A prominent detrimental function for IL-18 in APAP-induced ALI as proposed herein should relate to its pivotal role for hepatic expression of interferon-γ and Fas ligand, both of which aggravate APAP toxicity. As IL-18 serum levels increase in patients after APAP overdosing, targeting IL-18 may evolve as novel therapeutic option in those hard-to-treat patients where standard therapy with N-acetylcysteine is unsuccessful. Being a paradigmatic experimental model of ALI, current knowledge on ill-fated properties of IL-18 in APAP intoxication likewise emphasizes the potential of this cytokine to serve as therapeutic target in other entities of inflammatory liver diseases.

Introduction

Intended or unintended overdosing of acetaminophen [paracetamol, N-acetyl-p-aminophenol (APAP)] is regarded a major cause of acute liver failure provoking roughly 50,000 emergency room admissions, 2,500 hospitalizations, and 500 fatalities per year in the United States. The global burden on health-care systems that connects to APAP is based on a narrow therapeutic margin and supported by its broad over-the-counter availability. In fact, adverse consequences of APAP (self-)pharmacotherapy fuel a sustained discussion on safety issues and regulations regarding this fairly weak but frequently used analgesic drug (1–4).

Murine models of APAP-induced acute liver injury (ALI) are well established and adequately resemble key features of human intoxication (5). A crucial characteristic of APAP-induced ALI is centrilobular hepatocyte necrosis driven by N-acetyl-p-benzoquinone imine (NAPQI), an APAP metabolite generated by hepatic Cyp2e1 and Cyp1a2. Under the influence of NAPQI hepatocytes endure oxidative stress, malfunction of mitochondrial respiration, a drop in ATP, and predominantly necrotic cell death. Here, standard therapy with N-acetylcysteine interferes by providing NAPQI detoxifying glutathione (GSH) and by counteracting APAP-associated oxidative stress. Aforementioned noxious chain of events is amplified by cell intrinsic processes, among others activation of c-Jun N-terminal kinase (5–7). Since necrosis, by releasing danger-associated molecular patterns, notoriously connects to activation of innate immunity and inflammation (8), an additional immunological layer is considered a significant parameter determining APAP-induced ALI. Accordingly, several toll-like receptors (TLR) such as TLR4 (9, 10) and TLR3 (11) were reported to aggravate poisoning though conflicting reports impede straightforward interpretation (12, 13). Interestingly, TLR9 recognizing necrotic DNA has been identified consistently as pathogenic factor (12, 14, 15). Accordingly, TLR9 antagonism (16) or suppression of downstream type I interferon (IFN) function can ameliorate APAP toxicity (17, 18).

Whereas sterile liver inflammation is an undisputed consequence of APAP overdosing (5) its function is multifaceted and not fully understood. In this context, it must be appreciated that outcome of APAP poisoning is, to a significant degree, dependent on the capacity of the liver to activate repair and regeneration processes. Notably, in the later regenerative phase of intoxication, growth factors such as epidermal growth factor receptor ligands (19) but also pro-regenerative signal transducer and activator of transcription (STAT)-3-activating cytokines are regarded pivotal for efficient organ recovery (20). An interesting case in this context is interleukin (IL)-22 (21). Genetic models using IL22BP-deficient mice suggest a pathogenic role for endogenous IL-22 particularly during early intoxication (22). In contrast, administration of a single supra-physiological dose of recombinant IL-22 or its provision by liver-targeted IL-22 gene therapy mediates significant protection against APAP-induced ALI (23–25).

It adds to the overall complex nature of APAP-induced ALI that just sterile inflammation appears to be a prerequisite for activation of an efficient hepatic pro-regenerative program (20, 26).

A Complex Role for Paradigmatic Nuclear Factor (NF) κB-Activating IL-1 And TNFα In APAP-Induced ALI

Sterile inflammation is largely initiated by NF-κB-activating cytokines among which IL-1 and TNFα stand out as crucial (8, 27–29). Whereas hepatic upregulation of IL-1α/β during APAP-induced necroinflammation is undisputed (14, 30–32), the contribution of IL-1 to disease is undecided on every level of IL-1 biology. For example, inhibition of IL-1β maturation by lack of caspase-1 activity in C57BL/6 mice left APAP-induced ALI either unaffected (32, 33) or significantly bettered disease outcome (14). Notably, although IL-1α is not a caspase-1 substrate its protease activity is required for effective IL-1α release by monocytes (34). IL-1α/β-unresponsive IL-1 receptor-1 (IL-1R1)-deficient C57Bl/6 mice likewise displayed discordant behavior with either no effect (30) or amelioration of APAP intoxication (32, 35) put on record. Finally, administration of IL-1 receptor antagonist (IL-1Ra) (36) or neutralizing antibodies targeting either IL-1α (32) or IL-1β (14) improved APAP-induced ALI in C57Bl/6 mice. Surprisingly, IL-1Ra-deficient mice also displayed weakened intoxication (37), though BALB/c mice were used in that study. Alike IL-1, TNFα is evidently produced during APAP-induced ALI (11, 23, 38) and similarly puzzling with regard to function. Exemplarily, a report using TNFα-neutralizing antibody-treated or TNF receptor-1-deficient BALB/c mice proposed pathological action of this cytokine (39). Others found that TNFα-neutralization likewise inhibits (40) or is unable to influence (41) APAP toxicity in C57Bl/6 mice. Surprisingly, TNF receptor-1-deficiency actually aggravated disease in this mouse strain (42).

Differences in mouse characteristics, including the microbiome (43), as well as variations in APAP dosing may foster divergent conclusions regarding the role of IL-1 and TNFα in APAP-induced ALI. However, those observations may also echo an overlapping double-edged function of inflammation in the context of APAP overdosing. Specifically, while inflammation may initially promote early injury, hepatic repair and regeneration in a later phase of disease apparently rely on signals derived from innate immunity and associated cytokines. IL-1 and TNFα, for example, are able to upregulate pro-regenerative IL-6 as well as antioxidant pathways that enforce repair (20, 42, 44, 45). Some previous studies actually indicated a protective role of endogenous IL-1 (37) and TNFα (42) in APAP-induced ALI. Moreover, pro-inflammatory IL-36γ (46) was recently shown to promote regeneration in APAP toxicity, an observation that agrees with IL-36 supporting intestinal repair (47, 48). It is noteworthy that an early study reported on amelioration of APAP-induced ALI by application of recombinant IL-1α (49).

A Distinctive Role for IL-18 in APAP-Induced ALI

Due to some unique properties, IL-18 stands out among members of the IL-1 cytokine family (50, 51). IL-18 is constitutively expressed in a variety of cell types, for example, in hepatic Kupffer cells (52). Accordingly, IL-18 expression is detectable in healthy murine liver (53) where macrophages/Kupffer cells are a major source of bioactive IL-18 (50, 51). The active processed cytokine is usually (but not exclusively) generated by caspase-1 upon inflammatory stimulation (54). Besides being an inflammatory NF-κB-activating cytokine (55–57), two exceptional characteristics are key to the function of IL-18 in liver diseases. First of all, IL-18, initially coined IGIF for IFNγ-inducing factor (58), is pivotal for IFNγ production by T (58) and natural killer (NK) cells (59). In addition, IL-18 is a strong inducer of Fas ligand (FasL), particularly on NK cells (60). Both characteristics should be of significance for APAP-induced ALI because IFNγ (31) and Fas/FasL signaling (38, 61, 62) are crucial for the development of full APAP toxicity.

In accord with aforementioned characteristics, IL-18-deficient mice display strong protection from APAP-induced ALI (14). Since the pathogenic role of IL-18 in APAP intoxication has, best to our knowledge, not been confirmed in wild-type mice, we set out to determine consequences of IL-18 neutralization in this context. APAP (500 mg/kg) was applied intraperitoneally to fasted male C57Bl/6 mice as previously described (46). Where indicated, mice were i.v. cotreated with recombinant murine IL-18BPd:Fc (15 μg/mouse, R&D Systems, Wiesbaden, Germany). This genetically engineered agent corresponds to the neutralizing murine IL-18 opponent IL-18 binding protein d (IL-18BPd) (50, 63). Liver injury was quantified by determining serum alanine aminotransferase (ALT) activity 24 h after APAP administration, a time point coinciding with maximal hepatic damage in this protocol (46). In accord with data on IL-18-deficient mice, blockage of murine IL-18 biological activity by IL-18BPd:Fc indeed improved APAP-induced ALI (Figure 1A). As already alluded to, we and others have previously reported on amelioration of APAP intoxication by therapeutic provision of IL-22 (23–25). Interestingly, adding IL-22 (i.v. 3.5 μg/mouse, Immunotools, Friesoythe, Germany) to IL-18BPd:Fc further diminished serum ALT activity with an overall reduction by 69.5 ± 5.8% (Figure 1B). As further control, mice were i.v. treated with etanercept (75 μg/mouse, Pfizer, Karlsruhe, Germany), a clinically used TNFα blocker (TNFR2:Fc) known to likewise neutralize biological activity of the murine cytokine (64). As shown in Figure 1A, TNFα blockage did not affect APAP toxicity. Altogether, we confirm previous observations on a pathogenic role of IL-18 (14) and on lack of TNFα function (41) in APAP-induced ALI.

Figure 1View larger versionFigure 1. Effects of IL-18BPd:Fc on APAP-induced ALI. (A–C) All animal experiments (fasted male C57Bl/6 mice, 9–10 weeks old) were carried out in accordance with the recommendations of the Animal Protection Agency of the Federal State of Hessen (Regierungspräsidium Darmstadt, Germany). The protocol was approved by the Regierungspräsidium Darmstadt (Germany). The model of murine APAP (i.p. 500 mg/kg in 0.9% NaCl)-induced liver injury was performed as recently described (46). Where indicated, mice were i.v. cotreated with recombinant IL-18BPd:Fc (IL18BP), IL-22, or etanercept in PBS. (A) Mice received either APAP (n = 18), APAP/IL-18BPd:Fc (15 µg, n = 12), APAP/Etanercept (75 µg, n = 7), or 0.9% NaCl/PBS (ctrl, n = 6). After 24 h, serum alanine aminotransferase (ALT) activity was determined (Reflotron, Roche Diagnostics, Mannheim, Germany) and is depicted as units/liter (means ± SEM). *P < 0.05, ***P < 0.001 compared to ctrl; ###P < 0.001. (B) Mice received either APAP/PBS (n = 12), APAP/IL-18BPd:Fc (15 µg; n = 12), or APAP/IL-18BPd:Fc (15 µg) plus IL-22 (3.5 µg) (n = 13). After 24 h, serum ALT activity was determined and is depicted as units/liter (means ± SEM). $$$P < 0.001, #P < 0.05. (C) Mice received either APAP/PBS (n = 12) or APAP/IL-18BP (15 µg, n = 12) and were maintained for 16 h. For RNA analysis, liver tissue was snap frozen in liquid nitrogen and stored at −80°C. Total RNA was isolated as described (18). For real-time PCR, pre-developed reagents were used (Thermo Fisher Scientific, Darmstadt, Germany): GAPDH (VIC; 4352339E), Fas ligand (FasL) (FAM; Mm00438864_m1), and IFNγ (FAM; Mm01168134_m1). Assay mix was from Nippon Genetics (Düren, Germany). PCR: one initial step at 95°C (2 min) was followed by 40 cycles at 95°C (5 s) and 62°C (30 s). Detection of the dequenched probe, calculation of threshold cycles (CT values), and data analysis were performed by the Sequence Detector software (AbiPrism7500 Fast Sequence Detector, Thermo Fisher Scientific). Relative changes in hepatic FasL [(C), left panel] and IFNγ [(C), right panel] mRNA expression determined by real-time PCR were normalized to that of GAPDH and shown as fold-induction compared with untreated control mice (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with untreated control; #P < 0.05, ##P < 0.01. (A–C) Data are shown as means ± SEM. Raw data were analyzed by one-way ANOVA with post hoc Bonferroni correction. (D) Graphical summary of processes affecting outcome of APAP-induced ALI with focus on the pathogenic role of IL-18. Detrimental pathways activated by APAP overdosing are counteracted by endogenous mechanisms supporting organ recovery through repair and regeneration [e.g., hepatocyte STAT3 activation; expression of heat shock protein (Hsp)70 and glutamate-cysteine ligase (Gcl)]. If therapeutic NAC intervention aiming at augmentation of hepatocyte glutathione (GSH) fails due a to an exceedingly high APAP dosage, a too late time point of intervention, and/or a pre-damaged liver parenchyma, acute liver failure may proceed to an ill-fated condition requiring transplantation for patient survival. Here, IL-18 may play a unique role by supporting hepatic expression of FasL and IFNγ. Application of recombinant IL-18 binding protein (Tadekinig-a) may evolve as a novel therapeutic option to intervene at this point.

The pathogenic role of IL-18 during APAP-induced ALI likely connects to the aforementioned potential to upregulate hepatic IFNγ and FasL. Both latter parameters are increased in liver tissues of APAP-challenged mice (38). Administration of IL-18BPd:Fc in fact suppressed hepatic expression of FasL (Figure 1C, left panel) and IFNγ (Figure 1C, right panel) in APAP-treated mice. Interestingly, IFNγ is known to support hepatocyte necrosis in response to APAP, possibly by enhancing nitric oxide formation (5, 31). IFNγ may additionally impair APAP-associated liver regeneration (45). This detrimental IFNγ activity has been shown to determine course of disease in experimental partial hepatectomy (65). The pathogenic role of Fas/FasL in APAP-induced ALI is likewise well established, detectable in Fas- or FasL-deficient (38, 62) as well as in wild-type mice (61), and apparently mediated by non-canonical Fas action. Specifically, apoptosis of hepatocytes is not regarded as relevant mechanism contributing to APAP-induced ALI. Accordingly, hepatocyte apoptosis by Fas/FasL is largely ruled out as relevant pathogenic mechanism in that context (26). Although Fas is famous for mediating apoptosis, it is noteworthy that this receptor can also activate classical signal transduction, e.g., via mitogen-activated protein kinases and NF-κB (66) which disconnects from pro-apoptotic signaling (67). Pathogenic action of Fas in APAP-induced ALI has been related to downregulation of glutamate-cysteine ligase and prolongation of GSH depletion as well as to reduction of heat shock protein (HSP)-70 (62). HSP70 is protective in APAP poisoning (68) and actually supports liver regeneration in murine partial hepatectomy (69). Moreover, Fas deficiency connects to impaired expression of STAT3-activating IL-6 and IL-10 (62), both are capable of ameliorating APAP-induced ALI (20). It is a further remarkable facet that interactions between hepatic macrophages and lymphocytes directed by Fas/FasL actually support production of bioactive IL-18 in caspase-1-independent but caspase-8-dependent manner (70, 71). Since IL-18 enhances FasL expression (60) which in turn enhances IL-18 (70, 71) this regulatory path represents a classical vicious cycle promoting liver pathology (54). Figure 1D provides a graphical summary of the complex events affecting outcome of APAP-induced ALI with focus on the pathogenic role of IL-18.

Concluding Remarks

The unresolved role of NF-κB-activating inflammatory cytokines including that of the caspase-1/IL-1β axis in APAP-induced ALI (20, 26, 72–74)—see Table 1—may reflect Janus-faced properties of theses mediators in the early injury and the later (partly overlapping) regeneration phase of intoxication. Herein, we confirm and put forward the perspective that IL-18 plays a unique pathogenic role in this model of sterile inflammation. Regardless of whether being activated by caspase-1, caspase-8, or by extracellular proteases such as proteinase-3 (50, 54), the potential of mature IL-18 to upregulate hepatic IFNγ and FasL appears decisive for its function during APAP-induced ALI. It is noteworthy that a detrimental role for hepatic IL-18 is not only conceivable for APAP intoxication. Specifically, administration of IL-18 neutralizing antibodies or recombinant IL-18 binding protein likewise ameliorates Propionibacterium acnes/lipopolysaccharide- (53, 75) as well as concanavalin A-, Fas-, and Pseudomonas aeruginosa exotoxin A-induced murine liver damage (75). Moreover, treatment with recombinant IL-18 binding protein protected from liver injury in murine experimental hemophagocytic lymphohistiocytosis (76). Current data also suggest an additional benefit of the combination IL-18BPd:Fc plus IL-22, an observation that deserves delineation in forthcoming experiments.

See full tableTable 1. Data on the role of IL-18, IL-1, caspase-1, and TNFα in experimental APAP-induced ALI as detected in C57Bl/6 and BALB/c mice.

Current data altogether advocate short-term blockage of IL-18 as therapeutic approach in acute liver diseases. A recent phase I/II clinical trial investigating application of recombinant IL-18BP (tadekinig-α) in adult onset still’s disease actually revealed an acceptable safety profile of this agent—besides specific therapeutic efficacy (77). Moreover, in human acute liver failure due to APAP overdosing, elevated levels of IL-18 are detectable in patients’ sera (78). It is thus tempting to speculate that provision of interleukin-18 binding protein therapy aids those unfortunate patients where standard therapy with N-acetylcysteine falls short.

Ethics Statement

All animal experiments using C57Bl/6 mice (male, 9–10 weeks old) were carried out in accordance with the recommendations of the Animal Protection Agency of the Federal State of Hessen (Regierungspräsidium Darmstadt, Germany). The protocol was approved by the Regierungspräsidium Darmstadt (Germany).

Author Contributions

MB: performed all experiments, analyzed the data, and contributed to manuscript writing and editing. JP: analyzed the data and contributed to manuscript editing. HM: analyzed the data, designed the study, wrote the paper, and performed manuscript editing.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Footnotes

Funding. This work was supported by a grant from the DFG (MU 1284/6-1) to HM.

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

PMC Copyright Notice

The articles available from the PMC site are protected by copyright, even though access is free. Copyright is held by the respective authors or publishers who provide these articles to PMC. Users of PMC are responsible for complying with the terms and conditions defined by the copyright holder.

Users should assume that standard copyright protection applies to articles in PMC, unless an article contains an explicit license statement that gives a user additional reuse or redistribution rights. PMC does not allow automated/bulk downloading of articles that have standard copyright protection.

See the copyright notice on the PMC site, https://www.ncbi.nlm.nih.gov/pmc/about/copyright/, for further details and specific exceptions.

References

W BernalG AuzingerA DhawanJ Wendon. Acute liver failure. Lancet (2010) 376(9736):190–201.10.1016/S0140-6736(10)60274-720638564

WM Lee. Acetaminophen and the U.S. acute liver failure study group: lowering the risks of hepatic failure. Hepatology (2004) 40(1):6–9.10.1002/hep.2029315239078

WM Lee. Acetaminophen (APAP) hepatotoxicity-isn’t it time for APAP to go away? J Hepatol (2017) 67(6):1324–31.10.1016/j.jhep.2017.07.00528734939

K BruneB RennerG Tiegs. Acetaminophen/paracetamol: a history of errors, failures and false decisions. Eur J Pain (2015) 19(7):953–65.10.1002/ejp.62125429980

H JaeschkeY XieMR McGill. Acetaminophen-induced liver injury: from animal models to humans. J Clin Transl Hepatol (2014) 2(3):153–61.10.14218/JCTH.2014.0001426355817

JA HinsonDW RobertsLP James Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol (2010) 196:369–405.10.1007/978-3-642-00663-0_12

H BantelK Schulze-Osthoff. Mechanisms of cell death in acute liver failure. Front Physiol (2012) 3:79.10.3389/fphys.2012.0007922485095

T PradeuEL Cooper. The danger theory: 20 years later. Front Immunol (2012) 3:287.10.3389/fimmu.2012.0028723060876

J XuX ZhangM MonestierNL EsmonCT Esmon. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol (2011) 187(5):2626–31.10.4049/jimmunol.100393021784973

HC YoheKA O’HaraJA HuntTJ KitzmillerSG WoodJL Bement Involvement of toll-like receptor 4 in acetaminophen hepatotoxicity. Am J Physiol Gastrointest Liver Physiol (2006) 290(6):G1269–79.10.1152/ajpgi.00239.200516439473

KA CavassaniAP MoreiraD HabielT ItoAL CoelhoRM Allen Toll like receptor 3 plays a critical role in the progression and severity of acetaminophen-induced hepatotoxicity. PLoS One (2013) 8(6):e65899.10.1371/journal.pone.006589923762449

C CaiH HuangS WhelanL LiuB KautzaJ Luciano Benzyl alcohol attenuates acetaminophen-induced acute liver injury in a toll-like receptor-4-dependent pattern in mice. Hepatology (2014) 60(3):990–1002.10.1002/hep.2720124798499

AA GhaffariEK ChowSS IyerJC DengG Cheng. Polyinosinic-polycytidylic acid suppresses acetaminophen-induced hepatotoxicity independent of type I interferons and toll-like receptor 3. Hepatology (2011) 53(6):2042–52.10.1002/hep.2431621433044

AB ImaedaA WatanabeMA SohailS MahmoodM MohamadnejadFS Sutterwala Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome. J Clin Invest (2009) 119(2):305–14.10.1172/JCI3595819164858

PE MarquesAG OliveiraRV PereiraBA DavidLF GomidesAM Saraiva Hepatic DNA deposition drives drug-induced liver injury and inflammation in mice. Hepatology (2015) 61(1):348–60.10.1002/hep.2721624824608

R HoqueA FarooqA MalikBN TrawickDW BerberichJP McClurg A novel small-molecule enantiomeric analogue of traditional (-)-morphinans has specific TLR9 antagonist properties and reduces sterile inflammation-induced organ damage. J Immunol (2013) 190(8):4297–304.10.4049/jimmunol.120218423509352

S BhattacharyaKV KatlinskiM ReichertS TakanoA BriceB Zhao Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med (2014) 6:384–97.10.1002/emmm.20130323624480543

M BachmannZ WaiblerT PleliJ PfeilschifterH Mühl. Type I interferon supports inducible nitric oxide synthase in murine hepatoma cells and hepatocytes and during experimental acetaminophen-induced liver damage. Front Immunol (2017) 8:890.10.3389/fimmu.2017.0089028824623

B BhushanH ChavanP BorudeY XieK DuMR McGill Dual role of epidermal growth factor receptor in liver injury and regeneration after acetaminophen overdose in mice. Toxicol Sci (2017) 155(2):363–78.10.1093/toxsci/kfw21328123000

H Mühl. STAT3, a key parameter of cytokine-driven tissue protection during sterile inflammation—the case of experimental acetaminophen (paracetamol)-induced liver damage. Front Immunol (2016) 7:163.10.3389/fimmu.2016.0016327199988

H MühlP ScheiermannM BachmannL HärdleA HeinrichsJ Pfeilschifter. IL-22 in tissue-protective therapy. Br J Pharmacol (2013) 169(4):761–71.10.1111/bph.1219623530726

D KleinschmidtAD GiannouHM McGeeJ KempskiB SteglichFJ Huber A protective function of IL-22BP in ischemia reperfusion and acetaminophen-induced liver injury. J Immunol (2017) 199(12):4078–90.10.4049/jimmunol.170058729109123

P ScheiermannM BachmannI GorenB ZwisslerJ PfeilschifterH Mühl. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am J Pathol (2013) 182(4):1107–13.10.1016/j.ajpath.2012.12.01023375450

D FengY WangH WangH WengX KongBV Martin-Murphy Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol (2014) 193(5):2512–8.10.4049/jimmunol.140058825063867

W ChenX ZhangJ FanW ZaiJ LuanY Li Tethering interleukin-22 to apolipoprotein A-I ameliorates mice from acetaminophen-induced liver injury. Theranostics (2017) 7(17):4135–48.10.7150/thno.2095529158815

H JaeschkeCD WilliamsA RamachandranML Bajt. Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int (2012) 32(1):8–20.10.1111/j.1478-3231.2011.02501.x21745276

CA Dinarello A clinical perspective of IL-1β as the gatekeeper of inflammation. Eur J Immunol (2011) 41(5):1203–17.10.1002/eji.20114155021523780

H KonoA OndaT Yanagida. Molecular determinants of sterile inflammation. Curr Opin Immunol (2014) 26:147–56.10.1016/j.coi.2013.12.00424556412

R AllamSV KumarMN DarisipudiHJ Anders. Extracellular histones in tissue injury and inflammation. J Mol Med (Berl) (2014) 92(5):465–72.10.1007/s00109-014-1148-z24706102

CD WilliamsA FarhoodH Jaeschke. Role of caspase-1 and interleukin-1beta in acetaminophen-induced hepatic inflammation and liver injury. Toxicol Appl Pharmacol (2010) 247(3):169–78.10.1016/j.taap.2010.07.00420637792

Y IshidaT KondoT OhshimaH FujiwaraY IwakuraN Mukaida. A pivotal involvement of IFN-gamma in the pathogenesis of acetaminophen-induced acute liver injury. FASEB J (2002) 16(10):1227–36.10.1096/fj.02-0046com12153990

C ZhangJ FengJ DuZ ZhuoS YangW Zhang Macrophage-derived IL-1α promotes sterile inflammation in a mouse model of acetaminophen hepatotoxicity. Cell Mol Immunol (2017).10.1038/cmi.2017.22

CD WilliamsDJ AntoinePJ ShawC BensonA FarhoodDP Williams Role of the Nalp3 inflammasome in acetaminophen-induced sterile inflammation and liver injury. Toxicol Appl Pharmacol (2011) 252(3):289–97.10.1016/j.taap.2011.03.00121396389

K KuidaJA LippkeG KuMW HardingDJ LivingstonMS Su Altered cytokine export and apoptosis in mice deficient in interleukin-1 beta converting enzyme. Science (1995) 267(5206):2000–3.10.1126/science.75354757535475

CJ ChenH KonoD GolenbockG ReedS AkiraKL Rock. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med (2007) 13(7):851–6.10.1038/nm160317572686

J HuD YanJ GaoC XuY YuanR Zhu rhIL-1Ra reduces hepatocellular apoptosis in mice with acetaminophen-induced acute liver failure. Lab Invest (2010) 90(12):1737–46.10.1038/labinvest.2010.12720644519

T IshibeA KimuraY IshidaT TakayasuT HayashiK Tsuneyama Reduced acetaminophen-induced liver injury in mice by genetic disruption of IL-1 receptor antagonist. Lab Invest (2009) 89(1):68–79.10.1038/labinvest.2008.11019002106

ZX LiuS GovindarajanN Kaplowitz. Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 127(6):1760–74.10.1053/j.gastro.2004.08.05315578514

Y IshidaT KondoK TsuneyamaP LuT TakayasuN Mukaida. The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice. J Leukoc Biol (2004) 75(1):59–67.10.1189/jlb.040315214557383

A ChastreM BélangerE BeauchesneBN NguyenP DesjardinsRF Butterworth. Inflammatory cascades driven by tumor necrosis factor-alpha play a major role in the progression of acute liver failure and its neurological complications. PLoS One (2012) 7(11):e49670.10.1371/journal.pone.004967023166746

SB YeeM BourdiMJ MassonLR Pohl. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease. Chem Res Toxicol (2007) 20(5):734–44.10.1021/tx600349f17439248

H ChiuCR GardnerDM DambachJA BrittinghamSK DurhamJD Laskin Role of p55 tumor necrosis factor receptor 1 in acetaminophen-induced antioxidant defense. Am J Physiol Gastrointest Liver Physiol (2003) 285(5):G959–66.10.1152/ajpgi.00219.200312842828

B SchnablDA Brenner. Interactions between the intestinal microbiome and liver diseases. Gastroenterology (2014) 146(6):1513–24.10.1053/j.gastro.2014.01.02024440671

F BöhmUA KöhlerT SpeicherS Werner. Regulation of liver regeneration by growth factors and cytokines. EMBO Mol Med (2010) 2(8):294–305.10.1002/emmm.20100008520652897

N LiJ Hua. Immune cells in liver regeneration. Oncotarget (2017) 8(2):3628–39.10.18632/oncotarget.1227527690296

P ScheiermannM BachmannL HärdleT PleliA PiiperB Zwissler Application of IL-36 receptor antagonist weakens CCL20 expression and impairs recovery in the late phase of murine acetaminophen-induced liver injury. Sci Rep (2015) 5:8521.10.1038/srep0852125687687

O Medina-ContrerasA HarusatoH NishioKL FlanniganV NgoG Leoni Cutting edge: IL-36 receptor promotes resolution of intestinal damage. J Immunol (2016) 196(1):34–8.10.4049/jimmunol.150131226590314

K ScheibeI BackertS WirtzA HueberG SchettM Vieth IL-36R signalling activates intestinal epithelial cells and fibroblasts and promotes mucosal healing in vivo. Gut (2017) 66(5):823–38.10.1136/gutjnl-2015-31037426783184

M RenićF CuloA BilićZ BukovecD SabolovićZ Zupanović. The effect of interleukin 1 alpha on acetaminophen-induced hepatotoxicity. Cytokine (1993) 5(3):192–7.10.1016/1043-4666(93)90004-O8218930

CA DinarelloD NovickS KimG Kaplanski. Interleukin-18 and IL-18 binding protein. Front Immunol (2013) 4:289.10.3389/fimmu.2013.0028924115947

H MühlJ Pfeilschifter. Interleukin-18 bioactivity: a novel target for immunopharmacological anti-inflammatory intervention. Eur J Pharmacol (2004) 500(1–3):63–71.10.1016/j.ejphar.2004.07.01215464021

K MatsuiT YoshimotoH TsutsuiY HyodoN HayashiK Hiroishi Propionibacterium acnes treatment diminishes CD4+ NK1.1+ T cells but induces type I T cells in the liver by induction of IL-12 and IL-18 production from kupffer cells. J Immunol (1997) 159(1):97–106.9200444

H TsutsuiK MatsuiN KawadaY HyodoN HayashiH Okamura IL-18 accounts for both TNF-alpha- and fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol (1997) 159(8):3961–7.9378984

H TsutsuiS Nishiguchi. Importance of kupffer cells in the development of acute liver injuries in mice. Int J Mol Sci (2014) 15(5):7711–30.10.3390/ijms1505771124802875

S MatsumotoK Tsuji-TakayamaY AizawaK KoideM TakeuchiT Ohta Interleukin-18 activates NF-kappaB in murine T helper type 1 cells. Biochem Biophys Res Commun (1997) 234(2):454–7.10.1006/bbrc.1997.66659177292

AJ PurenG FantuzziY GuMS SuCA Dinarello. Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 101(3):711–21.10.1172/JCI13799449707

M BachmannC DragoiMA PoleganovJ PfeilschifterH Mühl. Interleukin-18 directly activates T-bet expression and function via p38 mitogen-activated protein kinase and nuclear factor-kappaB in acute myeloid leukemia-derived predendritic KG-1 cells. Mol Cancer Ther (2007) 6(2):723–31.10.1158/1535-7163.MCT-06-050517308068

H OkamuraH TsutsiT KomatsuM YutsudoA HakuraT Tanimoto Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature (1995) 378(6552):88–91.10.1038/378088a07477296

T ZhangK KawakamiMH QureshiH OkamuraM KurimotoA Saito. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun (1997) 65(9):3594–9.9284124

H TsutsuiK NakanishiK MatsuiK HigashinoH OkamuraY Miyazawa IFN-gamma-inducing factor up-regulates fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J Immunol (1996) 157(9):3967–73.8892629

H ZhangJ CookJ NickelR YuK SteckerK Myers Reduction of liver fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol (2000) 18(8):862–7.10.1038/7847510932156

CD WilliamsMR McGillA FarhoodH Jaeschke. Fas receptor-deficient lpr mice are protected against acetaminophen hepatotoxicity due to higher glutathione synthesis and enhanced detoxification of oxidant stress. Food Chem Toxicol (2013) 58:228–35.10.1016/j.fct.2013.04.03123628456

D NovickSH KimG FantuzziLL ReznikovCA DinarelloM Rubinstein. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 10(1):127–36.10.1016/S1074-7613(00)80013-810023777

BK PopivanovaK KitamuraY WuT KondoT KagayaS Kaneko Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest (2008) 118(2):560–70.10.1172/JCI3245318219394

R SunB Gao. Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma). Gastroenterology (2004) 127(5):1525–39.10.1053/j.gastro.2004.08.05515521020

M Le GalloA PoissonnierP BlancoP Legembre. CD95/Fas, non-apoptotic signaling pathways, and kinases. Front Immunol (2017) 8:1216.10.3389/fimmu.2017.0121629021794

R ImamuraK KonakaN MatsumotoM HasegawaM FukuiN Mukaida Fas ligand induces cell-autonomous NF-kappaB activation and interleukin-8 production by a mechanism distinct from that of tumor necrosis factor-alpha. J Biol Chem (2004) 279(45):46415–23.10.1074/jbc.M40322620015337758

JK TolsonDJ DixRW VoellmySM Roberts. Increased hepatotoxicity of acetaminophen in Hsp70i knockout mice. Toxicol Appl Pharmacol (2006) 210(1–2):157–62.10.1016/j.taap.2005.10.00116280147

JH WolfTR BhattiS FouraschenS ChakravortyL WangS Kurian Heat shock protein 70 is required for optimal liver regeneration after partial hepatectomy in mice. Liver Transpl (2014) 20(3):376–85.10.1002/lt.2381324357103

H TsutsuiN KayagakiK KuidaH NakanoN HayashiK Takeda Caspase-1-independent, fas/fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice. Immunity (1999) 11(3):359–67.10.1016/S1074-7613(00)80111-910514014

L BossallerPI ChiangC Schmidt-LauberS GanesanWJ KaiserVA Rathinam Cutting edge: FAS (CD95) mediates noncanonical IL-1β and IL-18 maturation via caspase-8 in an RIP3-independent manner. J Immunol (2012) 189(12):5508–12.10.4049/jimmunol.120212123144495

BL WoolbrightH Jaeschke. Role of the inflammasome in acetaminophen-induced liver injury and acute liver failure. J Hepatol (2017) 66(4):836–48.10.1016/j.jhep.2016.11.01727913221

P KubesWZ Mehal Sterile inflammation in the liver. Gastroenterology (2012) 143(5):1158–72.10.1053/j.gastro.2012.09.00822982943

JJ Maher. DAMPs ramp up drug toxicity. J Clin Invest (2009) 119(2):246–9.19244605

R FaggioniRC CattleyJ GuoS FloresH BrownM Qi IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of fas/fas ligand-mediated models of liver disease in mice. J Immunol (2001) 167(10):5913–20.10.4049/jimmunol.167.10.591311698468

L ChiossoneS AudonnetB ChetailleL ChassonC FarnarierY Berda-Haddad Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol (2012) 3:239.10.3389/fimmu.2012.0023922891066

C GabayB FautrelJ RechF SpertiniE FeistI Koetter Open-label, multicenter, dose-escalating phase ii clinical trial on the safety and efficacy of tadekinig alpha in adult onset still’s disease. Ann Rheum Dis (2017) 76:70910.1136/annrheumdis-2017-eular.2336

DG CraigP LeeEA PrydeE HidalgoPC HayesSJ Wigmore Markedly increased high-mobility group box 1 protein in a patient with small-for-size syndrome. Case Rep Transplant (2014) 2014:272498.10.1155/2014/27249824600525

[Back]

Figure 1.

Effects of IL-18BPd:Fc on APAP-induced ALI. (A–C) All animal experiments (fasted male C57Bl/6 mice, 9–10 weeks old) were carried out in accordance with the recommendations of the Animal Protection Agency of the Federal State of Hessen (Regierungspräsidium Darmstadt, Germany). The protocol was approved by the Regierungspräsidium Darmstadt (Germany). The model of murine APAP (i.p. 500 mg/kg in 0.9% NaCl)-induced liver injury was performed as recently described (46). Where indicated, mice were i.v. cotreated with recombinant IL-18BPd:Fc (IL18BP), IL-22, or etanercept in PBS. (A) Mice received either APAP (n = 18), APAP/IL-18BPd:Fc (15 µg, n = 12), APAP/Etanercept (75 µg, n = 7), or 0.9% NaCl/PBS (ctrl, n = 6). After 24 h, serum alanine aminotransferase (ALT) activity was determined (Reflotron, Roche Diagnostics, Mannheim, Germany) and is depicted as units/liter (means ± SEM). *P < 0.05, ***P < 0.001 compared to ctrl; ###P < 0.001. (B) Mice received either APAP/PBS (n = 12), APAP/IL-18BPd:Fc (15 µg; n = 12), or APAP/IL-18BPd:Fc (15 µg) plus IL-22 (3.5 µg) (n = 13). After 24 h, serum ALT activity was determined and is depicted as units/liter (means ± SEM). $$$P < 0.001, #P < 0.05. (C) Mice received either APAP/PBS (n = 12) or APAP/IL-18BP (15 µg, n = 12) and were maintained for 16 h. For RNA analysis, liver tissue was snap frozen in liquid nitrogen and stored at −80°C. Total RNA was isolated as described (18). For real-time PCR, pre-developed reagents were used (Thermo Fisher Scientific, Darmstadt, Germany): GAPDH (VIC; 4352339E), Fas ligand (FasL) (FAM; Mm00438864_m1), and IFNγ (FAM; Mm01168134_m1). Assay mix was from Nippon Genetics (Düren, Germany). PCR: one initial step at 95°C (2 min) was followed by 40 cycles at 95°C (5 s) and 62°C (30 s). Detection of the dequenched probe, calculation of threshold cycles (CT values), and data analysis were performed by the Sequence Detector software (AbiPrism7500 Fast Sequence Detector, Thermo Fisher Scientific). Relative changes in hepatic FasL [(C), left panel] and IFNγ [(C), right panel] mRNA expression determined by real-time PCR were normalized to that of GAPDH and shown as fold-induction compared with untreated control mice (n = 6). *P < 0.05, **P < 0.01, ***P < 0.001 compared with untreated control; #P < 0.05, ##P < 0.01. (A–C) Data are shown as means ± SEM. Raw data were analyzed by one-way ANOVA with post hoc Bonferroni correction. (D) Graphical summary of processes affecting outcome of APAP-induced ALI with focus on the pathogenic role of IL-18. Detrimental pathways activated by APAP overdosing are counteracted by endogenous mechanisms supporting organ recovery through repair and regeneration [e.g., hepatocyte STAT3 activation; expression of heat shock protein (Hsp)70 and glutamate-cysteine ligase (Gcl)]. If therapeutic NAC intervention aiming at augmentation of hepatocyte glutathione (GSH) fails due a to an exceedingly high APAP dosage, a too late time point of intervention, and/or a pre-damaged liver parenchyma, acute liver failure may proceed to an ill-fated condition requiring transplantation for patient survival. Here, IL-18 may play a unique role by supporting hepatic expression of FasL and IFNγ. Application of recombinant IL-18 binding protein (Tadekinig-a) may evolve as a novel therapeutic option to intervene at this point.

[Back]

[Back]

Table 1.

Data on the role of IL-18, IL-1, caspase-1, and TNFα in experimental APAP-induced ALI as detected in C57Bl/6 and BALB/c mice.

IL-18 blockage | ↓ IL-18BPd:Fc (herein); ↓ il18−/− mice (14)
IL-1-blockage | ≈ il1r1−/− mice (30)
| ↓ il1r1−/− mice (32, 35); ↓ anti-IL-1β (14); ↓ anti-IL-1α (32)
IL-1 receptor antagonist deficiency | ↓ il1ra−/− mice (37), using BALB/c mice
Casp-1 blockage | ≈ casp1−/− (32, 33)
| ↓ casp1−/−( (14)
TNFα blockage | ≈ Etanercept (herein); ≈ anti-TNFα (41)
| ↑ TNF-R-p55−/− (42)
| ↓ anti-TNFα (39) using BALB/c mice (40)
| ↓ TNF-R-p55⁻/( [(39) using BALB/c mice]

Unless otherwise indicated, data were generated using C57Bl/6 mice.

Casp-1, caspase-1; ≈, lack of effect; ↓, amelioration of disease; ↑ aggravation of disease.

[Back]